KAINOS Laboratories, Inc. develops, manufactures, markets, distributes, and imports/exports pharmaceuticals, diagnostic reagents, related chemical products, physical and chemical measurement instruments, medical supplies, nutrition supplements, foodstuff, animal feed, and related products in Japan. The company offers various biochemical clinical testing reagents systems, such as Aqua-auto Kainos series for automated analysis equipment; MP-EIA series for automated EIA equipment QUARTUS ImmunoCube; Lana 1,5AG, a high-sensitivity diabetes diagnostic reagent and a family of immunoserological testing reagents; MAST, an allergic diagnostic reagent; and Hitazyme Chlamydia for infectious diseases. It also provides FGF-23 ELISA Kit, a two-site enzyme-linked immunosorbent assay kit for the measurement of FGF-23 in serum; and ADAMTS13 ELISA kit that captures ADAMTS13-cleaved products using a sandwich method. In addition, the company offers biochemical diagnostic reagents, including Aqua-auto Kainos UN-II test kit, a liquid form urea nitrogen measurement reagent kit; Aqua-auto Kainos CRE-II test kit, a liquid form creatinine measurement reagent kit; and Aqua-auto Kainos ALB test kit, a liquid form reagent kit. Further, it provides Swiftgene Norovirus GI/GII Kainos for detecting noroviruses; Statmark FLUstickAB for detecting Type A and Type B influenza virus antigens; and Statmark Strep A for detecting Group A-b hemolytic streptococci. The company was formerly known as DOMS-IATRON Co., Ltd. and changed its name to KAINOS Laboratories, Inc. in July 1975. KAINOS Laboratories, Inc. was founded in 1975 and is headquartered in Tokyo, Japan.
kainos laboratories inc
(4556:Tokyo Stock Exchange)
38-18, Hongo 2-chome
|No competitor information is available for 4556.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact KAINOS LABORATORIES INC, please visit www.kainos.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.